OMCL

SEC source: 0001415889-22-006768 · form4-06172022_020631.xml · nonDerivative · entry 2

Seidelmann Scott Peter · CIK 0001736895 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,547

F2 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021.

F3 · price: The price reported in Column 4 is an exact price of $108.56 for all shares sold.

SEC source: 0001415889-22-006772 · form4-06172022_020656.xml · nonDerivative · entry 1

Manley Corey J · CIK 0001928727 · SR. VP & CHIEF LEGAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,619

F1 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of restricted stock units.

SEC source: 0001415889-22-006771 · form4-06172022_020603.xml · nonDerivative · entry 1

LIPPS RANDALL A · CIK 0001227556 · Director · CHAIRMAN, PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,062

F1 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of restricted stock units.

SEC source: 0001415889-22-006770 · form4-06172022_020626.xml · nonDerivative · entry 1

Kuipers Peter J. · CIK 0001651691 · EXECUTIVE V P& CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,326

F1 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of restricted stock units.

SEC source: 0001415889-22-006769 · form4-06172022_020650.xml · nonDerivative · entry 1

SPEARS JOSEPH BRIAN · CIK 0001729964 · CHIEF ACCOUNTING OFFICER & SVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,239

F1 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of restricted stock units.

SEC source: 0001415889-22-006768 · form4-06172022_020631.xml · nonDerivative · entry 1

Seidelmann Scott Peter · CIK 0001736895 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,554

F1 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of restricted stock units.

SEC source: 0001415889-22-006767 · form4-06172022_020653.xml · nonDerivative · entry 1

MELLON CHRISTINE MARIE · CIK 0001848442 · EVP, CHIEF ADMIN & PEOPLE

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,883

F1 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of restricted stock units.

SEC source: 0001415889-22-006766 · form4-06172022_020647.xml · nonDerivative · entry 1

JOHNSTON DAN S · CIK 0001271802 · EVP, EXECUTIVE ADVISOR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,730

F1 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of restricted stock units.

SEC source: 0001415889-22-005694 · form4-05262022_010549.xml · nonDerivative · entry 1

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,181

F1 · shares: Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board member, pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001415889-22-005692 · form4-05262022_010550.xml · nonDerivative · entry 1

Bousa Edward Peter · CIK 0001452605 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,139

F1 · shares: Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board member, pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001415889-22-005690 · form4-05262022_010547.xml · nonDerivative · entry 1

Moore Vance B. · CIK 0001550553 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,751

F1 · shares: Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board member, pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001415889-22-005688 · form4-05262022_010528.xml · nonDerivative · entry 1

Seim Robin Gene · CIK 0001351911 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,672

F1 · shares: Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board member, pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001415889-22-005686 · form4-05262022_010552.xml · nonDerivative · entry 1

WHITE SARA J · CIK 0001227559 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,534

F1 · shares: Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board member, pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001415889-22-005684 · form4-05262022_010535.xml · nonDerivative · entry 1

Bauer Joanne B · CIK 0001359343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,882

F1 · shares: Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board member, pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001415889-22-005680 · form4-05262022_010503.xml · nonDerivative · entry 1

Garrett Mary · CIK 0001663588 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,511

F1 · shares: Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board member, pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001415889-22-005682 · form4-05262022_010528.xml · nonDerivative · entry 1

Scott Bruce E · CIK 0001776980 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,246

F1 · shares: Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board member, pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001415889-22-005408 · form4-05202022_010531.xml · nonDerivative · entry 1

Manley Corey J · CIK 0001928727 · SR. VP & CHIEF LEGAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,054

F1 · shares: Restricted Stock Units ("RSUs") granted in connection with the Issuer's equity incentive plan. RSUs shall vest semiannually on 6/15 and 12/15 for a period of four years.

SEC source: 0001415889-22-005406 · form4-05202022_010536.xml · nonDerivative · entry 1

SPEARS JOSEPH BRIAN · CIK 0001729964 · CHIEF ACCOUNTING OFFICER & SVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,377

F1 · shares: Restricted Stock Units granted in connection with the Issuer's equity incentive plan. One-fourth (25%) of the shares subject to the grant shall vest one year after the grant date with a vesting date that is either: (i) 2/15; (ii) 5/15; (iii) 8/15 or (iv) 11/15 based on which of those four dates is the closest date following the one-year anniversary of the date of grant. The remaining three-fourths (75%) of the shares subject to the grant shall vest quarterly over three years on: (i) 2/15; (ii) 5/15; (iii) 8/15; and (iv) 11/15.

SEC source: 0001179110-22-002639 · edgar.xml · derivative · entry 3

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,278

Underlying: Common Stock · 2,000 shares

Expires 2022-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Option Exercised and held in the account.

SEC source: 0001179110-22-002639 · edgar.xml · nonDerivative · entry 2

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Option Exercised and held in the account.

F1 · price: Option Exercised and held in the account.

SEC source: 0001179110-22-002420 · edgar.xml · derivative · entry 3

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,278

Underlying: Common Stock · 2,000 shares

Expires 2022-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Option Exercised and held in the account.

SEC source: 0001179110-22-002420 · edgar.xml · nonDerivative · entry 2

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Option Exercised and held in the account.

F1 · price: Option Exercised and held in the account.

SEC source: 0001179110-22-002278 · edgar.xml · nonDerivative · entry 4

Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,380

F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9,2021.

F4 · price: The price reported in Column 4 is an exact price of $133.11 for all shares sold.

SEC source: 0001179110-22-002273 · edgar.xml · nonDerivative · entry 2

SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,257

F3 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of restricted stock units.

SEC source: 0001179110-22-002279 · edgar.xml · nonDerivative · entry 3

JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,891

F2 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units.

SEC source: 0001179110-22-002279 · edgar.xml · nonDerivative · entry 2

JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,754

F1 · shares: Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 4,760 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 9,520 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

F1 · balance_after: Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 4,760 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 9,520 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

SEC source: 0001179110-22-002278 · edgar.xml · nonDerivative · entry 3

Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,905

F2 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units.

SEC source: 0001179110-22-002278 · edgar.xml · nonDerivative · entry 2

Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,140

F1 · shares: Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 9,520 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 19,040 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

F1 · balance_after: Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 9,520 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 19,040 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

SEC source: 0001179110-22-002276 · edgar.xml · nonDerivative · entry 3

MELLON CHRISTINE MARIE · CIK 0001848442 · EVP, Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,110

F2 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units.

SEC source: 0001179110-22-002276 · edgar.xml · nonDerivative · entry 2

MELLON CHRISTINE MARIE · CIK 0001848442 · EVP, Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,947

F1 · shares: Reflects performance-based restricted stock units that were previously granted on March 2, 2021, subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 6,595 shares on Form 4 filed on March 4, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 13,190 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

F1 · balance_after: Reflects performance-based restricted stock units that were previously granted on March 2, 2021, subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 6,595 shares on Form 4 filed on March 4, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 13,190 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

SEC source: 0001179110-22-002274 · edgar.xml · nonDerivative · entry 3

Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,519

F2 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units.

SEC source: 0001179110-22-002274 · edgar.xml · nonDerivative · entry 2

Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,199

F1 · shares: Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 9,520 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 19,040 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

F1 · balance_after: Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 9,520 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 19,040 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

SEC source: 0001179110-22-002275 · edgar.xml · nonDerivative · entry 5

LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,790

F4 · shares: Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units.

SEC source: 0001179110-22-002275 · edgar.xml · nonDerivative · entry 4

LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,729

F3 · shares: Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 20,715 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 41,430 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

F3 · balance_after: Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 20,715 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 41,430 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

SEC source: 0001179110-22-002153 · edgar.xml · derivative · entry 3

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,278

Underlying: Common Stock · 2,000 shares

Expires 2022-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Option Exercised and held in the account.

SEC source: 0001179110-22-002153 · edgar.xml · nonDerivative · entry 2

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Option Exercised and held in the account.

F1 · price: Option Exercised and held in the account.

SEC source: 0001179110-22-001527 · edgar.xml · derivative · entry 3

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,278

Underlying: Common Stock · 3,000 shares

Expires 2022-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Option Exercised and held in the account.

SEC source: 0001179110-22-001527 · edgar.xml · nonDerivative · entry 2

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Option Exercised and held in the account.

F1 · price: Option Exercised and held in the account.

SEC source: 0001179110-22-001406 · edgar.xml · nonDerivative · entry 4

LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,014

F4 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years.

SEC source: 0001179110-22-001405 · edgar.xml · nonDerivative · entry 2

MELLON CHRISTINE MARIE · CIK 0001848442 · EVP, Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,352

F2 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years.

SEC source: 0001179110-22-001403 · edgar.xml · nonDerivative · entry 2

JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,994

F2 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years.

SEC source: 0001179110-22-001404 · edgar.xml · nonDerivative · entry 2

Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,620

F1 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years

SEC source: 0001179110-22-001402 · edgar.xml · nonDerivative · entry 2

Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,679

F2 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years.

SEC source: 0001179110-22-001291 · edgar.xml · derivative · entry 3

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires 2022-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Option Exercised and held in the account.

F1 · derivative.underlying_shares: Option Exercised and held in the account.

SEC source: 0001179110-22-001291 · edgar.xml · nonDerivative · entry 2

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-22-001005 · edgar.xml · derivative · entry 3

Moore Vance B. · CIK 0001550553 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,951

Underlying: Common Stock · 25,951 shares

Expires 2022-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.underlying_shares: Option Exercised and held in the account.

SEC source: 0001179110-22-001005 · edgar.xml · nonDerivative · entry 2

Moore Vance B. · CIK 0001550553 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Option Exercised and held in the account.

SEC source: 0001179110-21-011070 · edgar.xml · nonDerivative · entry 6

JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,831

F5 · price: The price reported in Column 4 is a weighted average price of $178.48. The shares were sold in multiple transactions at prices ranging from $178.13 to $178.83. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001179110-21-011070 · edgar.xml · nonDerivative · entry 5

JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,039

F4 · price: The price reported in Column 4 is a weighted average price of $177.36. The shares were sold in multiple transactions at prices ranging from $177.04 to $177.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001179110-21-011070 · edgar.xml · nonDerivative · entry 4

JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,159

F3 · price: The price reported in Column 4 is a weighted average price of $176.69. The shares were sold in multiple transactions at prices ranging from $176.30 to $176.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.